Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7795340 | 0.87 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1LMNATP53KMT2A | |
| SCHEMBL20856173 | 0.87 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1LMNATP53KMT2A | |
| SCHEMBL472178 | 0.85 | ALDH1A1 (0.38) | ALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL20162506 | 0.85 | ALDH1A1 (0.38) | ALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL20162548 | 0.85 | KDM4E (0.34) | SMN1; SMN2ALDH1A1LMNATP53KMT2A | |
| SCHEMBL7030455 | 0.85 | KDM4E (0.34) | SMN1; SMN2ALDH1A1LMNATP53KMT2A | |
| SCHEMBL7028386 | 0.83 | PTGIR (0.39) | — | |
| SCHEMBL22321965 | 0.83 | KDM4E (0.36) | SMN1; SMN2ALDH1A1LMNATP53KMT2A | |
| SCHEMBL382026 | 0.83 | KDM4E (0.36) | SMN1; SMN2ALDH1A1LMNATP53KMT2A | |
| SCHEMBL20162518 | 0.82 | KDM4E (0.38) | SMN1; SMN2ALDH1A1LMNATP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2025-05-22 | — | — | US | disclosed |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2024-08-06 | — | — | US | disclosed |
| US-20220306675-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2022-09-29 | — | — | US | disclosed |
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2022-06-07 | — | — | US | disclosed |
| EP-3683225-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | Nucana PLC (GB) | 2020-07-22 | — | — | EP | disclosed |
| US-20200181189-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
| US-10570168-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds | NuCana plc (GB) | 2020-02-25 | — | — | US | disclosed |
| EP-3224268-B1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2019-06-26 | — | — | EP | disclosed |
| EP-3224268-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana BioMed Limited (GB) | 2017-10-04 | — | — | EP | disclosed |
| US-20170253629-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NUCANA BIOMED LIMITED (GB) | 2017-09-07 | — | — | US | disclosed |
| WO-2016083830-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NUCANA BIOMED LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
| WO-2012040126-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306675-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, ADORA2A | SMN1; SMN2 2870/4885ALDH1A1 2246/4885LMNA 1393/4885 |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, ADA, ADORA2A | SMN1; SMN2 2913/4885ALDH1A1 2198/4885LMNA 1328/4885 |
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, RNMT, ADA | SMN1; SMN2 2634/4885ALDH1A1 2162/4885LMNA 1196/4885 |
| US-10570168-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds | MTAP, RNMT, ADA | SMN1; SMN2 2634/4885ALDH1A1 2162/4885LMNA 1196/4885 |
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, ADORA2A | SMN1; SMN2 2870/4885ALDH1A1 2246/4885LMNA 1393/4885 |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | SMN1; SMN2 1718/4885ALDH1A1 2210/4885LMNA 2798/4885 |
| US-20200181189-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, RNMT | SMN1; SMN2 2591/4885ALDH1A1 2194/4885LMNA 1256/4885 |
| US-20170253629-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, RNMT | SMN1; SMN2 2591/4885ALDH1A1 2194/4885LMNA 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.